MORAGA, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of the Company and the Director of Pain Research at Stanford University School of Medicine, presented at the American Headache Society (AHS) 56th Annual Scientific Meeting held on June 26-29, 2014, in Los Angeles, California. Dr. Yeomans was selected by the AHS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy. His presentation occurred on June 28, 2014.
Help employers find you! Check out all the jobs and post your resume.
